三七通舒胶囊联合阿司匹林治疗老年冠心病的安全性及对凝血酶原时间国际标准化比率、D-二聚体和凝血酶原时间的影响

目的 探究三七通舒胶囊联合阿司匹林治疗老年冠心病的安全性及对凝血酶原时间国际标准化比率（PT-INR）、D-二聚体（D-D）、凝血酶原时间（PT）的影响。方法 选取绵阳市中医医院在2012年1月—2015年12月收治的、符合纳入标准的老年冠心病患者90例。根据治疗方法不同分为对照组（n=45）及观察组（n=45）。对照组给予患者控制血压、血糖、血脂等常规治疗，同时口服拜阿司匹林0.1 g/次，1次/d，睡前服用；观察组在对照组基础上联合三七通舒胶囊200 mg/次，3次/d；疗程均为6个月。对比两组治疗前后PT-INR、D-D、PT、血小板聚集功能（PAgT）、肝肾功能指标及不良反应情况。结果 治疗后，两组PAgT及D-D降低，PT及PT-INR延长，同组治疗前后比较差异均有统计学意义（P<0.05）；观察组PAgT、PT、PT-INR均高于对照组，差异具有统计学意义（P<0.05）。两组治疗前后的丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、血尿素氮（BUN）及血肌酐（Cr）差异无统计学意义。观察组的不良反应发生率（4.44%）明显低于对照组（24.44%），差异有统计学意义（P<0.05）。结论 三七通舒胶囊联合阿司匹林治疗老年冠心病是安全、有效的。

Effect of Sanqi Tongshu Capsule on safety of elderly patients with coronary heart disease and its effects on PT-INR, D-D and PT

Objective To explore the effect of sanqi saponins on the safety of elderly patients with coronary heart disease and its effects on PT-INR, D-D and PT. Methods 90 elderly patients with coronary heart disease in our hospital from January 2012 to December 2015 were selected into the clinical data. The patients were divided into the control group (n=45) and the experimental group (n=45) by random number table. The control group was treated with aspirin, the experimental group was treated with Sanqi Tongshu Capsule. The PT-INR, D-D, PT, PAgT, liver and kidney indexes and adverse reactions were compared between the two groups before and after treatment. Results After treatment, PAgT and D-D decreased significantly (P<0.05), PT and PT-INR prolongation significantly (P<0.05). The PAgT, PT and PT-INR in the experimental group were higher than those in the control group (P<0.05). The difference of ALT, AST, BUN and Cr between the two groups before and after treatment were not statistically significant. The incidence of adverse reactions in the experimental group was significantly lower than that in the control group (24.44% vs 4.44%, P=0.02). Conclusions Sanqi Tongshu Capsule is safe and effective in the treatment of senile coronary heart disease.